SCHEMBL2591555

SCHEMBL2591555

CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N(C)C)nc2)cc2c1cnn2C(C)C

nearest known ligand 0.78

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
EZH2 Q15910 15/20 0.78
EZH1 Q92800 12/20 0.75
PRMT3 O60678 2/20 0.74
EED O75530 2/20 0.74
RBBP4 Q09028 2/20 0.74
SUZ12 Q15022 2/20 0.74
RBBP7 Q16576 2/20 0.74
AEBP2 Q6ZN18 2/20 0.74
SETD7 Q8WTS6 2/20 0.74
ADRA1B P35368 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12180852 0.91 EZH2 (0.73) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL2592809 0.91 EZH2 (0.83) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL12180849 0.90 EZH2 (0.81) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL26184189 0.90 EZH2 (0.81) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL2588648 0.89 EZH2 (0.82) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL2594244 0.89 EZH2 (0.84) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL2595606 0.88 EZH2 (0.78) EZH2EZH1PRMT3EEDRBBP4
Hydrochloric Acid SCHEMBL2594023 0.88 EZH2 (0.81) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL12180744 0.88 EZH2 (0.60) EZH2EZH1PRMT3EEDRBBP4
SCHEMBL2595926 0.87 EZH2 (0.81) EZH2EZH1PRMT3EEDRBBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP claimed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US claimed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US claimed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH2 1599/4885EZH1 1398/4885PRMT3 343/4885
US-20140350013-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH2 1599/4885EZH1 1398/4885PRMT3 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.